Clinical Trials Directory

Trials / Conditions / Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

12 registered clinical trials studyying Relapsed or Refractory B-cell Non-Hodgkin Lymphoma — 5 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingA Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
NCT06970496
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.Phase 1
RecruitingPemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
NCT06300528
University of UtahPhase 2
SuspendedTazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-ce
NCT06824701
University of UtahPhase 1
RecruitingA Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lym
NCT06173518
Autolus LimitedPhase 1
Active Not RecruitingA Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
NCT05784441
Janssen Research & Development, LLCPhase 1
RecruitingA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
NCT06565689
Excyte Biopharma LtdPhase 1
UnknownGZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT05797948
The First Affiliated Hospital of Soochow UniversityN/A
CompletedStudy of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT05008055
AstraZenecaPhase 2
UnknownCD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malig
NCT05105867
920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaEARLY_Phase 1
RecruitingA Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (M
NCT06189391
MSD R&D (China) Co., Ltd.Phase 1
UnknownStudy of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Ho
NCT02981745
Centaurus Biopharma Co., Ltd.Phase 1 / Phase 2
UnknownGene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
NCT02134262
Jichi Medical UniversityPhase 1 / Phase 2